Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results

Oncolytics Biotech (ONCY) Reports Q3 Loss of $0.16

November 11, 2020 4:52 PM EST

Oncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.16), versus ($0.16) reported last year.

Financial Highlights

As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million during the third quarter through the issuing of common stock through our ATM facility.Operating expense for the third quarter of 2020 was $2.5 million, compared to $1.8 million in the third quarter of 2019.R&D expense for the third quarter of 2020 was $3.9 million, compared to $1.7 million in the third quarter of 2019.Net cash used in operating activities for the third... More